![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status
Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status
March 14, 2016
Canadian drugmaker Soricimed Biopharma has secured orphan drug designation for its peptide SOR-C13 for treatment of ovarian cancer.
SOR-C13 targets TRPV6, a calcium channel prevalent in prostate, breast, lung and ovarian cancer.
Upcoming Events
-
21Oct